Rui Liang
Publications by Year
Research Areas
Receptor Mechanisms and Signaling, Lanthanide and Transition Metal Complexes, Diabetes Treatment and Management, Magnetism in coordination complexes, Computational Drug Discovery Methods
Most-Cited Works
- → An orally available non-nucleotide STING agonist with antitumor activity(2020)621 cited
- → Discovery of a Novel Glucagon Receptor AntagonistN-[(4-{(1S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes(2012)86 cited
- → From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9(2019)81 cited
- → Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor(2005)57 cited
- → Discovery and Pharmacology of a Novel Class of Diacylglycerol Acyltransferase 2 Inhibitors(2015)25 cited
- → Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor(2006)20 cited
- → GPR109a agonists. Part 1: 5-Alkyl and 5-aryl-pyrazole–tetrazoles as agonists of the human orphan G-protein coupled receptor GPR109a(2009)20 cited
- → GPR109a agonists. Part 2: Pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a(2010)13 cited
- → Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol.(2011)7 cited
- → VEGF aptamer/i-motif-grafted multi-functional SPION nanocarrier for chemotherapeutic/phototherapeutic synergistic research(2021)5 cited